Tower Research Capital (TRC)’s Voyager Therapeutics VYGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.9K | Sell |
2,257
-1,090
| -33% | -$4.13K | ﹤0.01% | 4107 |
|
|
2026
Q1 | $12.9K | Buy |
3,347
+611
| +22% | +$2.4K | ﹤0.01% | 3766 |
|
|
2025
Q4 | $10.8K | Sell |
2,736
-7,371
| -73% | -$32.6K | ﹤0.01% | 3711 |
|
|
2025
Q3 | $47.2K | Buy |
10,107
+941
| +10% | +$3.4K | ﹤0.01% | 2568 |
|
|
2025
Q2 | $28.5K | Buy |
9,166
+1,064
| +13% | +$3.43K | ﹤0.01% | 3450 |
|
|
2025
Q1 | $27.4K | Buy |
8,102
+2,719
| +51% | +$12.7K | ﹤0.01% | 2684 |
|
|
2024
Q4 | $30.5K | Buy |
5,383
+3,077
| +133% | +$19.8K | ﹤0.01% | 2891 |
|
|
2024
Q3 | $13.5K | Sell |
2,306
-8,647
| -79% | -$62.9K | ﹤0.01% | 3516 |
|
|
2024
Q2 | $86.6K | Buy |
10,953
+10,534
| +2,514% | +$88.3K | ﹤0.01% | 2679 |
|
|
2024
Q1 | $3.9K | Sell |
419
-5,980
| -93% | -$50.5K | ﹤0.01% | 4772 |
|
|
2023
Q4 | $54K | Buy |
6,399
+4,809
| +302% | +$34.9K | ﹤0.01% | 3084 |
|
|
2023
Q3 | $12.3K | Sell |
1,590
-335
| -17% | -$3.06K | ﹤0.01% | 3903 |
|
|
2023
Q2 | $22K | Buy |
1,925
+1,177
| +157% | +$12.2K | ﹤0.01% | 3303 |
|
|
2023
Q1 | $6K | Sell |
748
-5,748
| -88% | -$45.7K | ﹤0.01% | 4888 |
|
|
2022
Q4 | $40K | Buy |
+6,496
| New | +$36.9K | ﹤0.01% | 2520 |
|
|
2022
Q2 | – | Sell |
-19,339
| Closed | -$147K | – | 6564 |
|
|
2022
Q1 | $147K | Sell |
19,339
-23,627
| -55% | -$105K | ﹤0.01% | 1958 |
|
|
2021
Q4 | $116K | Buy |
42,966
+30,238
| +238% | +$103K | ﹤0.01% | 2142 |
|
|
2021
Q3 | $34K | Buy |
12,728
+6,980
| +121% | +$22.7K | ﹤0.01% | 3272 |
|
|
2021
Q2 | $24K | Buy |
5,748
+1,132
| +25% | +$5.13K | ﹤0.01% | 3736 |
|
|
2021
Q1 | $21K | Buy |
4,616
+3,267
| +242% | +$22.3K | ﹤0.01% | 3853 |
|
|
2020
Q4 | $10K | Sell |
1,349
-7,673
| -85% | -$73.8K | ﹤0.01% | 4328 |
|
|
2020
Q3 | $96K | Buy |
9,022
+4,871
| +117% | +$57.2K | ﹤0.01% | 3176 |
|
|
2020
Q2 | $52K | Buy |
+4,151
| New | +$48.3K | ﹤0.01% | 3016 |
|
|
2019
Q4 | – | Sell |
-539
| Closed | -$9K | – | 4444 |
|
|
2019
Q3 | $9K | Buy |
+539
| New | +$11.3K | ﹤0.01% | 3018 |
|
|
2019
Q2 | – | Sell |
-7,775
| Closed | -$149K | – | 4364 |
|
|
2019
Q1 | $149K | Buy |
7,775
+6,225
| +402% | +$81.1K | 0.01% | 1254 |
|
|
2018
Q4 | $15K | Buy |
+1,550
| New | +$19.9K | ﹤0.01% | 2178 |
|
|
2018
Q3 | – | Sell |
-151
| Closed | -$3K | – | 4291 |
|
|
2018
Q2 | $3K | Buy |
+151
| New | +$2.98K | ﹤0.01% | 3262 |
|
|
2018
Q1 | – | Sell |
-534
| Closed | -$9K | – | 3892 |
|
|
2017
Q4 | $9K | Sell |
534
-1,809
| -77% | -$31K | ﹤0.01% | 2631 |
|
|
2017
Q3 | $48K | Buy |
+2,343
| New | +$26.4K | ﹤0.01% | 2023 |
|
|
2016
Q4 | – | Sell |
-1,084
| Closed | -$13K | – | 4459 |
|
|
2016
Q3 | $13K | Buy |
+1,084
| New | +$14.7K | ﹤0.01% | 1893 |
|
|
2016
Q2 | – | Sell |
-3,450
| Closed | -$30K | – | 5040 |
|
|
2016
Q1 | $30K | Buy |
3,450
+2,840
| +466% | +$32.2K | ﹤0.01% | 1073 |
|
|
2015
Q4 | $13K | Buy |
+610
| New | +$14.1K | ﹤0.01% | 1817 |
|
Other funds holding VYGR
AC
VPC
OM
Tower Research Capital (TRC)'s VYGR Position: Q2 2026 in Review
Tower Research Capital (TRC) reduced its Voyager Therapeutics (VYGR) stake by 33% in Q2 2026, selling an estimated $4.13K and leaving 2,257 shares worth $7.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4107.
Tower Research Capital (TRC) first reported a position in VYGR in Q4 2015 and has held it in 32 quarters since. The position peaked at $149K in Q1 2019. 136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.
- Tower Research Capital (TRC) held 2,257 shares of Voyager Therapeutics worth $7.9K as of Q2 2026.
- Tower Research Capital (TRC) sold 1,090 Voyager Therapeutics shares in Q2 2026, an estimated $4.13K.
- Voyager Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4107 holding.
- Tower Research Capital (TRC) first reported a position in Voyager Therapeutics in Q4 2015 and has held it in 32 quarters since.
- Tower Research Capital (TRC)'s Voyager Therapeutics position peaked at $149K in Q1 2019.
- 136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.